The Carlyle Group has selected Robert Yates as chief operating officer of Ortho-Clinical Diagnostics subject to the close of Carlyle’s acquisition of OCD from Johnson & Johnson. In this newly-created role, Yates will report directly to incoming OCD chairman and CEO Dr. Martin Madaus.
Global alternative asset manager The Carlyle Group (NASDAQ:CG) today announced that Robert Yates will become Chief Operating Officer of Ortho-Clinical Diagnostics, Inc. (“OCD”), subject to the close of Carlyle’s acquisition of OCD from Johnson & Johnson, which is expected in mid-2014. In this newly-created role, Mr. Yates will report directly to incoming OCD Chairman and CEO Dr. Martin Madaus. Mr. Yates will also be appointed to OCD’s board of directors.
“We are excited at the prospect of having Robert’s diagnostics and executive leadership experience on board at OCD,” said Stephen H. Wise, Carlyle Managing Director. “In partnership with Martin, Robert will contribute significantly to OCD’s transformation into a global standalone diagnostics leader.” Dr. Martin Madaus added, “Robert’s strategic perspective and proven leadership abilities align well with OCD’s new priorities of profitable growth and differentiated innovation for our customers and for patients around the world.”
Mr. Yates will join OCD from Merck KGaA where he was President and CEO of EMD/Merck Millipore, its global life sciences division. At EMD Millipore, Robert finalized the complex transition of Millipore from a standalone company into one integrated, global Life Science division. He increased the discipline and execution on market-led innovation, redefined the go-to-market approach, and implemented a suite of unified global processes, systems and business tools while optimizing the organizational structure. Under Robert´s leadership, EMD Millipore consistently delivered above market quality growth and eliminated systemic product quality and supply related disruptions.
Robert joined Millipore from the diagnostics division of Roche, where he led Roche Applied Science, the life sciences business located in Penzberg, Germany. In that role, he also served as a member of the Diagnostics Executive Committee. Robert joined Roche in Indianapolis, Indiana in 1988 and held various roles in R&D, Engineering and Operations before being appointed Global Head of Business Development and Licensing in Basel, Switzerland in 2003. He possesses a wealth of experience in the Diagnostics and Life Science industries and a strong background in integrating global businesses, building performance cultures and delivering strategic business value. He holds a Bachelor of Science degree in Electrical Engineering from Purdue University in Indiana.
* * * * *
About Ortho-Clinical Diagnostics, Inc.
Ortho-Clinical Diagnostics, Inc. delivers the high-quality in vitro diagnostic products that give healthcare professionals around the world the knowledge they need to make better treatment decisions sooner. The company serves the global transfusion medicine community with donor screening and blood typing products to help ensure every patient receives blood that is safe, the right type and the right unit. Ortho-Clinical Diagnostics, Inc. also brings sophisticated information management, testing technologies and automation and interpretation tools to clinical laboratories worldwide to help them run more efficiently and improve patient care.
About The Carlyle Group
The Carlyle Group (NASDAQ: CG) is a global alternative asset manager with approximately $199 billion of assets under management across 120 funds and 133 fund of funds vehicles as of March 31, 2014. Carlyle’s purpose is to invest wisely and create value on behalf of its investors, many of whom are public pensions. Carlyle invests across four segments – Corporate Private Equity, Real Assets, Global Market Strategies and Solutions – in Africa, Asia, Australia, Europe, the Middle East, North America and South America. Carlyle has expertise in various industries, including: aerospace, defense & government services, consumer & retail, energy, financial services, healthcare, industrial, real estate, technology & business services, telecommunications & media and transportation. The Carlyle Group employs more than 1,600 people in 38 offices across six continents.